AXDXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:20):

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East...

Stats
本日の出来高	2 737.00
平均出来高	72 770.00
時価総額	20.17M
EPS	$0 ( 2024-03-28 )
次の収益日	( $-0.720 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.190
ATR14	$0.0190 (2.04%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-17	Phillips Jack	Buy	59 928	Common Stock
2024-04-17	Phillips Jack	Sell	26 735	Common Stock
2024-04-17	Phillips Jack	Sell	59 928	Employee Restricted Stock Units
2024-04-12	Phillips Jack	Buy	59 928	Common Stock
2024-04-12	Phillips Jack	Sell	26 545	Common Stock

INSIDER POWER
96.80
Last 100 transactions
Buy: 51 589 751 \| Sell: 625 027

Accelerate Diagnostics 相関

10 最も正の相関
APOP	0.891
SONM	0.887
EA	0.881
MRACW	0.861
RBNC	0.857
ALIM	0.856
SVOK	0.849
EQRX	0.848
GHVI	0.847
PAIC	0.843

10 最も負の相関
MMAC	-0.943
PKW	-0.908
PID	-0.902
VONV	-0.9
IUSV	-0.896
PVAL	-0.896
LOPE	-0.895
IOSP	-0.894
TCFC	-0.892
RNDV	-0.89

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Accelerate Diagnostics 財務諸表

Annual	2023
収益:	$12.06M
総利益:	$2.55M (21.15 %)
EPS:	$-4.94

FY	2023
収益:	$12.06M
総利益:	$2.55M (21.15 %)
EPS:	$-4.94

FY	2022
収益:	$12.75M
総利益:	$3.30M (25.90 %)
EPS:	$-7.61

FY	2021
収益:	$11.78M
総利益:	$-381 000 (-3.23 %)
EPS:	$-1.260

Financial Reports:

No articles found.

Accelerate Diagnostics

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.